Boryeong-si, South Korea

Byeong Uk Jeon

USPTO Granted Patents = 1 



Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Byeong Uk Jeon

Introduction

Byeong Uk Jeon is a notable inventor based in Boryeong-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in cancer treatment. His work focuses on developing innovative compounds that can effectively target specific mutations associated with cancer.

Latest Patents

Byeong Uk Jeon holds a patent for a compound titled "N2,N4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer." This invention relates to a derivative that exhibits a relatively weak inhibitory effect on wild-type EGFR but shows high inhibitory ability on EGFR mutations and FLT3 mutations. The compound can be effectively utilized for treating cancers associated with these mutations and demonstrates a synergy effect when administered in combination with other treatments.

Career Highlights

Jeon is affiliated with the Korea Research Institute of Chemical Technology, where he continues to advance his research in chemical technology and pharmaceuticals. His innovative approach to drug development has positioned him as a key figure in the fight against cancer.

Collaborations

He has collaborated with notable colleagues, including Kwangho Lee and Inji Shin, to further enhance the research and development of effective cancer treatments.

Conclusion

Byeong Uk Jeon's contributions to pharmaceutical innovation, particularly in cancer treatment, highlight the importance of targeted therapies in modern medicine. His work continues to inspire advancements in the field and offers hope for improved treatment options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…